Cytokine therapy of allergic rhinitis

Noriaki Aoi, Hideyuki Kawauchi, Yasunobu Yoshikai

    Research output: Contribution to journalArticle

    Abstract

    In the nasal mucosa of patients with allergic rhinitis, CD4+T precursor cells have been demonstrated to predominantly differentiate into Th2 cells rather than into Th1 cells. Cytokine therapy has been generally accepted to redress the imbalance of differentiation of Th0 into a Th1 or Th2 environment. To date, there are no reports about cytokine therapy for human allergic rhinitis, although there are a number of reports about general cytokine therapy in murine models of allergic rhinitis. Topical cytokine therapy has not been extensively investigated, however, recently, intranasal administration of cytokine, vector and antisense-nucleotide has been reported. The nasal mucosa presents numerous advantages as a target tissue for drug delivery, such as a large mucosal area, rapid absorption, no pH or enzyme barrier, and no first-pass metabolism. The permeability of various particles through nasal mucosa is limited by the tight junctions present in abundance. Therefore, the feasibility and disadvantages of cytokine therapy are discussed in detail in this report.

    Original languageEnglish
    Pages (from-to)43-47
    Number of pages5
    JournalOto-Rhino-Laryngology Tokyo
    Volume51
    Issue numberSUPPL. 1
    Publication statusPublished - Aug 1 2008

    Fingerprint

    Cytokines
    Nasal Mucosa
    Therapeutics
    T-Lymphoid Precursor Cells
    Intranasal Administration
    Th2 Cells
    Th1 Cells
    Tight Junctions
    Allergic Rhinitis
    Permeability
    Nucleotides
    Enzymes
    Pharmaceutical Preparations

    All Science Journal Classification (ASJC) codes

    • Otorhinolaryngology

    Cite this

    Aoi, N., Kawauchi, H., & Yoshikai, Y. (2008). Cytokine therapy of allergic rhinitis. Oto-Rhino-Laryngology Tokyo, 51(SUPPL. 1), 43-47.

    Cytokine therapy of allergic rhinitis. / Aoi, Noriaki; Kawauchi, Hideyuki; Yoshikai, Yasunobu.

    In: Oto-Rhino-Laryngology Tokyo, Vol. 51, No. SUPPL. 1, 01.08.2008, p. 43-47.

    Research output: Contribution to journalArticle

    Aoi, N, Kawauchi, H & Yoshikai, Y 2008, 'Cytokine therapy of allergic rhinitis', Oto-Rhino-Laryngology Tokyo, vol. 51, no. SUPPL. 1, pp. 43-47.
    Aoi N, Kawauchi H, Yoshikai Y. Cytokine therapy of allergic rhinitis. Oto-Rhino-Laryngology Tokyo. 2008 Aug 1;51(SUPPL. 1):43-47.
    Aoi, Noriaki ; Kawauchi, Hideyuki ; Yoshikai, Yasunobu. / Cytokine therapy of allergic rhinitis. In: Oto-Rhino-Laryngology Tokyo. 2008 ; Vol. 51, No. SUPPL. 1. pp. 43-47.
    @article{397168ccffa740ca9c02ecc8034bce92,
    title = "Cytokine therapy of allergic rhinitis",
    abstract = "In the nasal mucosa of patients with allergic rhinitis, CD4+T precursor cells have been demonstrated to predominantly differentiate into Th2 cells rather than into Th1 cells. Cytokine therapy has been generally accepted to redress the imbalance of differentiation of Th0 into a Th1 or Th2 environment. To date, there are no reports about cytokine therapy for human allergic rhinitis, although there are a number of reports about general cytokine therapy in murine models of allergic rhinitis. Topical cytokine therapy has not been extensively investigated, however, recently, intranasal administration of cytokine, vector and antisense-nucleotide has been reported. The nasal mucosa presents numerous advantages as a target tissue for drug delivery, such as a large mucosal area, rapid absorption, no pH or enzyme barrier, and no first-pass metabolism. The permeability of various particles through nasal mucosa is limited by the tight junctions present in abundance. Therefore, the feasibility and disadvantages of cytokine therapy are discussed in detail in this report.",
    author = "Noriaki Aoi and Hideyuki Kawauchi and Yasunobu Yoshikai",
    year = "2008",
    month = "8",
    day = "1",
    language = "English",
    volume = "51",
    pages = "43--47",
    journal = "Oto-Rhino-Laryngology Tokyo",
    issn = "0386-9687",
    publisher = "Society of Oto-Rhino-Laryngology Tokyo",
    number = "SUPPL. 1",

    }

    TY - JOUR

    T1 - Cytokine therapy of allergic rhinitis

    AU - Aoi, Noriaki

    AU - Kawauchi, Hideyuki

    AU - Yoshikai, Yasunobu

    PY - 2008/8/1

    Y1 - 2008/8/1

    N2 - In the nasal mucosa of patients with allergic rhinitis, CD4+T precursor cells have been demonstrated to predominantly differentiate into Th2 cells rather than into Th1 cells. Cytokine therapy has been generally accepted to redress the imbalance of differentiation of Th0 into a Th1 or Th2 environment. To date, there are no reports about cytokine therapy for human allergic rhinitis, although there are a number of reports about general cytokine therapy in murine models of allergic rhinitis. Topical cytokine therapy has not been extensively investigated, however, recently, intranasal administration of cytokine, vector and antisense-nucleotide has been reported. The nasal mucosa presents numerous advantages as a target tissue for drug delivery, such as a large mucosal area, rapid absorption, no pH or enzyme barrier, and no first-pass metabolism. The permeability of various particles through nasal mucosa is limited by the tight junctions present in abundance. Therefore, the feasibility and disadvantages of cytokine therapy are discussed in detail in this report.

    AB - In the nasal mucosa of patients with allergic rhinitis, CD4+T precursor cells have been demonstrated to predominantly differentiate into Th2 cells rather than into Th1 cells. Cytokine therapy has been generally accepted to redress the imbalance of differentiation of Th0 into a Th1 or Th2 environment. To date, there are no reports about cytokine therapy for human allergic rhinitis, although there are a number of reports about general cytokine therapy in murine models of allergic rhinitis. Topical cytokine therapy has not been extensively investigated, however, recently, intranasal administration of cytokine, vector and antisense-nucleotide has been reported. The nasal mucosa presents numerous advantages as a target tissue for drug delivery, such as a large mucosal area, rapid absorption, no pH or enzyme barrier, and no first-pass metabolism. The permeability of various particles through nasal mucosa is limited by the tight junctions present in abundance. Therefore, the feasibility and disadvantages of cytokine therapy are discussed in detail in this report.

    UR - http://www.scopus.com/inward/record.url?scp=53749098036&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=53749098036&partnerID=8YFLogxK

    M3 - Article

    AN - SCOPUS:53749098036

    VL - 51

    SP - 43

    EP - 47

    JO - Oto-Rhino-Laryngology Tokyo

    JF - Oto-Rhino-Laryngology Tokyo

    SN - 0386-9687

    IS - SUPPL. 1

    ER -